Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

NovaBay Pharmaceuticals Receives Noncompliance Notice from NYSE MKT

NovaBay Pharmaceuticals,Inc.
Posted on: 19 May 17

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) today announced receipt of a letter from NYSE MKT LLC (“NYSE MKT” or the “Exchange”) on May 16, 2017, stating that it is not in compliance with the continued listing standards (requiring stockholders’ equity of $6.0 million or more if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years) as set forth in Section 1003(a)(iii) of the NYSE MKT Company Guide (“Company Guide”).

In order to maintain its listing, NovaBay Pharmaceuticals must submit a plan of compliance by June 15, 2017, addressing how it intends to regain compliance with Section 1003(a)(iii) of the Company Guide.

The Company intends to submit a plan to regain compliance with NYSE MKT listing standards. If the plan is not accepted, delisting proceedings will commence. If the plan is accepted, the Company’s common stock will continue to be listed on the NYSE MKT during the plan period. However, if the Company does not regain compliance with those standards or does not make progress consistent with the plan, the NYSE MKT staff may commence delisting proceedings.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics ®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the  Apple Store  or  Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website

NovaBay Contacts
For NovaBay Avenova purchasing information, please contact:

View source version on

Business Wire

Last updated on: 19/05/2017

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.